HO CHI MINH CITY, Vietnam, May 27, 2026 /PRNewswire/ -- Gold (XAU/USD) maintains its leading position in CFD traders' portfolios. Due to changing expectations about inflation rates, central bank policies, and geopolitical events, gold remains one of the most important tools in traders' strategies.
When working with CFD assets such as XAU/USD, the quality of the trading process is as important as the choice of approach. Efficient execution is essential for achieving desired results when applying certain strategies to gold.
Price Volatility and High Liquidity of the Instrument
Like many other assets, gold reacts to macroeconomic news. The main factors influencing price movements are interest rates, the strength of the USD, and inflation.
The asset demonstrates high liquidity, ensuring it is readily tradable. However, price volatility rises sharply on the days of significant macroeconomic data releases. In such conditions, the precision of trade execution becomes important, as traders need to manage slippage and widening spreads.
Sensitivity to Spreads
Spreads are a crucial element in determining the success of many traders' strategies. Tight spreads make it possible to carry out operations with minimal risk of deviations due to price movements.
It is necessary to pay attention to the following aspects:
- Spreads in both favorable and unfavorable market conditions.
- Speed of order execution and the ability to secure a better entry point in the event of high price movement.
- Quality of slippage control and its presence during the publication of important macroeconomic data.
In the current situation, traders analyze not just the average spreads offered by a broker, but also the stability and consistency of those spreads. Brokers such as JustMarkets provide access to competitive spreads and execution infrastructure designed to support trading in both stable and volatile market conditions.
Using Leverage
Leverage plays an important role in increasing the profitability of a trading strategy. With this tool, it is possible to increase the size of a position using relatively small amounts of capital.
Leverage up to 1:3000 is allowed when trading gold. At the same time, using this option requires careful organization, as the trader is exposed to greater risk.
By implementing a trading system and managing risk effectively, it is possible to use leverage and trade gold while maintaining flexibility in investment amounts.
Swap-Free Conditions for Overnight Trading
Position trading involves holding a position for the long term. This method requires opening a position over several candles and monitoring price changes.
In this case, the trader faces overnight commissions, which can be significant. To solve the problem, many traders use swap-free trading conditions, which exclude overnight costs from the account. Brokers like JustMarkets offer swap-free account options, allowing traders to maintain positions overnight without additional swap charges on eligible instruments.
Conditions of Platform Work and Analysis
To implement any trading strategy successfully, you need a platform. In addition to reliability and speed, the platform should provide traders with analytical opportunities, such as the ability to use indicators. On this basis, traders can analyze market conditions and choose the right moment to execute trades.
Platforms such as MetaTrader 4 and 5, among others, enable traders to implement trading strategies by providing access to indicators and charting tools.
Importance of Technical Conditions
Gold responds to many factors of global economic development, which determine its behavior. To trade this asset effectively, it is necessary to use certain conditions and technical features.
Risk Warning: Trading financial instruments involves significant risk and may not be suitable for all investors. Market conditions can change rapidly, and losses may exceed deposits. This article is for informational purposes only and does not constitute investment advice.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Gold (XAU/USD) Trading Conditions - JustMarkets Emphasizes Execution Quality
Highlights:
- Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
- Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
- Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
- The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
- Based on current enrolment momentum, Neurizon anticipates that last participant dosing will now occur in Q2 CY2027 with topline results to be released early Q3 CY2027, exceeding previous trial timeframe projection
- Expanded participant cohort cost is materially offset by a contribution of philanthropic funds from the Sean M. Healey & AMG Center for ALS at Mass General Brigham
- As a result of diligent cost management and rapid recruitment, this change is expected to have no impact on Neurizon's costs through to topline results and only a very modest increase in the total cost of completing the full trial
- Larger, consistent dataset expected to strengthen partnering and commercial positioning for NUZ-001
- 113 participants assigned and 74 dosed as of 22 May 2026, with 64 US clinical trial sites activated and 193 participants screened under the master protocol to date
- Neurizon to host a shareholder webinar on 28 May to discuss the trial recruitment expansion in further detail
MELBOURNE, Australia, May 27, 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to advise that Regimen I of the HEALEY ALS Platform Trial will increase its total patient cohort from 160 to 240 participants. The expansion is driven by the enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period. Expanded design maintains statistical power for the primary endpoint aligned with the original assumptions underpinning the study and allows more robust analysis of subgroups and biomarkers.
Importantly, the current recruitment momentum is expected to accelerate the overall trial timeline relative to previous expectations, despite the increased recruitment target. Based on current trends, the Company now anticipates last participant dosing in Q2 CY2027, with topline results expected in early Q3 CY2027.
Following an extensive review of the scientific, statistical, financial and regulatory considerations, as well as ongoing engagement with the Sean M. Healey & AMG Center, Regimen I will now comprise 180 NUZ-001 participants and 60 Regimen I placebo controls.
As of 22 May 2026, 113 participants have been assigned to Regimen I and 74 participants have been dosed. There are 64 clinical trial sites activated across the United States and 193 participants have been screened to date under the master protocol. While current recruitment momentum continues to track ahead of prior expectations, future recruitment rates may vary over time.
Based on the expanded 240-patient design, accelerated enrolment timelines and a meaningful financial contribution of philanthropic funds from the Sean M. Healey & AMG Center for ALS at Mass General Brigham, Neurizon expects the total funding requirements through to study completion to remain unchanged.
Neurizon remains focused on efficiently delivering a scientifically meaningful outcome from the HEALEY ALS Platform Trial. The expansion of the trial has no impact on Neurizon's expected costs through to topline results, with only a modest overall increase in the total cost of completing the full trial. This increase is expected to be further offset through eligibility under the Australian Federal Government's R&D Tax Incentive Program, together with the financial contribution of philanthropic funds from the Sean M. Healey & AMG Center for ALS at Mass General Brigham. This demonstrates Neurizon's continued focus on cost and capital efficiency and ensures the Company remains fully funded through completion of the trial.
Neurizon believes expanding the regimen is a fiscally disciplined and strategically attractive decision to generate a larger, more statistically robust, and internally consistent ALS dataset, which eliminates reliance on placebo groups from other regimens and maintains the original statistical assumptions underpinning the study at topline results.
Interim Executive Chairman, Mr Sergio Duchini said: "The expansion of Regimen I to 240 participants reflects our considerable confidence in NUZ-001 and is underpinned by strong momentum being delivered across the HEALEY ALS Platform Trial study. Importantly, this decision maintains the statistical power for the analysis of the primary endpoint and the potential for topline results ahead of our previously stated schedule."
"The strength of recruitment and engagement across the HEALEY ALS Platform Trial network has positioned Neurizon to proactively optimise the study design at an important point in the trial. We believe the expanded dataset will strengthen the statistical robustness, interpretability and strategic value of the program as we advance toward topline results."
"Importantly, the larger and more internally consistent dataset is expected to enhance future regulatory, partnering and commercial opportunities for NUZ-001, while also strengthening our ability to generate valuable biomarker and translational insights relevant to the broader neurodegenerative disease landscape."
"ALS remains an area of urgent unmet medical need, and we believe this decision further strengthens Neurizon's positioning as we continue advancing NUZ-001 through late-stage clinical development."
Merit Cudkowicz, MD, MSc, Director of the Healey & AMG Center and Executive Director of the Mass General Brigham Neuroscience Institute, said: "This partnership with Neurizon reflects a shared commitment to advancing meaningful science while keeping people living with ALS at the center of everything we do. We thank our patient advisory committee members and the entire ALS community for active participation in this important clinical trial. By working collaboratively, we can accelerate progress, strengthen the research ecosystem, and ultimately deliver solutions that better serve the ALS community."
Sabrina Paganoni, MD, PhD, Co-Principal Investigator of the HEALEY ALS Platform Trial and Co-Director of the Neurological Clinical Research Institute (NCRI) said: "I want to sincerely thank the Network of Excellence for ALS (NEALS) investigators and site teams for achieving our most rapid enrollment to date — an extraordinary milestone that reflects their dedication and collaboration. I also want to recognize the coordination center at the Healey & AMG Center and key vendors for outstanding implementation and execution of the study, which made this success possible, as well as participants and their families for their dedication and support."
About the HEALEY ALS Platform Trial:
The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo controlled adaptive Phase 2/3 clinical trial conducted by the Sean M. Healey & AMG Center for ALS at Mass General Brigham in the United States (US), created in partnership with the Network of Excellence for ALS (NEALS). Entry into the HEALEY ALS Platform Trial is competitive, with drug candidates reviewed and selected by expert committees based on scientific merit and evidence of potential benefit in ALS. The goal of the HEALEY ALS Platform Trial is to accelerate the development of potential new ALS therapies.
This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.
Neurizon® is a registered trademark of Neurizon Therapeutics Limited
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
HEALEY ALS Platform Trial Regimen I expands to 240 participants
